Press releases Archives - Page 6 of 13

Press releases

Apr

2025

New discoveries in infection biology, highlighting the rich potential of non-antibiotic treatments of infections

Hamlet Biopharma

Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, announces the publication of new sci...

Apr

2025

New scientific advances for Alpha1H highlight the unique discovery pipeline and drug development potential for the treatment of bladder cancer

Hamlet Biopharma

Press releases

Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, announces the publication of new sci...

Apr

2025

New granted patents added to Hamlet BioPharma’s extensive patent portfolio in cancer and infection

Hamlet Biopharma

Press releases

Hamlet BioPharma’s extensive patent portfolio comprises 147 granted patents and 33 pending cases. Strategy regarding intellectual property right...

Apr

2025

Strong Alpha1H treatment effects confirmed in patients with bladder cancer, in final analysis. Clinical study report is being completed for submission to the FDA.

Hamlet Biopharma

Press releases

Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, announces that Hamlet BioPharma’s dr...

Mar

2025

Hamlet BioPharma bjuder in till investerarmöte den 12 mars

Hamlet Biopharma

Press releases

Som tidigare meddelats bjuder Hamlet BioPharma in till månatligt investerarmöte onsdagen den 12 mars, 2025, klockan 12.00. Klicka på länken nedan för ...

Mar

2025

Kommuniké från extra bolagsstämma i Hamlet BioPharma AB (publ) den 11 mars 2025

Hamlet Biopharma

Press releases

Vid extra bolagsstämma i Hamlet BioPharma AB (publ), org.nr 556568-8958, (”Hamlet BioPharma” eller ”Bolaget”) idag den 11 mars 2025 fattades bland ann...

Feb

2025

Hamlet BioPharma bjuder in till investerarmöte den 21 februari

Hamlet Biopharma

Press releases

Med anledning av Pressmeddelanden och nyheter bjuder Hamlet BioPharma in till investerarmöte fredagen den 21 februari, 2025, klockan 12.00. Bolaget k...

Feb

2025

Kallelse till extra bolagsstämma i Hamlet BioPharma AB (publ)

Hamlet Biopharma

Press releases

Aktieägarna i Hamlet BioPharma AB (publ) (”Hamlet BioPharma” eller ”Bolaget”), org.nr 556568-8958, kallas härmed till extra bolagsstämma tisdagen den ...

Feb

2025

The board of Hamlet BioPharma proposes licensing agreement with Linnane Pharma, which creates conditions for an effective commercialization of Bamlet and positive value for both companies

Hamlet Biopharma

Press releases

Hamlet BioPharma AB (“Hamlet BioPharma” or the “Company”), an innovative pharmaceutical company that develops new therapies a...

Feb

2025

Elisabeth Parker appointed as Business development expert in Hamlet BioPharma and joins the team on March 3rd

Hamlet Biopharma

Press releases

Hamlet BioPharma has appointed Elisabeth Parker, PhD to strengthen the business development expertise in the company. Dr. Parker has 25 years’ experi...

« Previous

Pressrelease – Lund, March 30th, 2026 – Hamlet BioPharma presented at the Financial Stockholm event on March 26, 2026

March 30, 2026

Pressrelease – Lund, 24 Mars, 2026 – Hamlet BioPharma tillförs cirka 8.5 miljoner kronor genom teckning av teckningsoptioner serie TO5B, s.k. korta optioner

March 24, 2026

Pressrelease – Lund, March 17th, 2026 – Hamlet BioPharmas digital monthly investor meeting on the 18th of March

March 17, 2026

Pressrelease – Lund, 15 mars 2026 – Styrelsen beslutar om justering av villkoren för teckningsoptioner av serie TO5B och inför ny kompletterande teckningsperiod 16-23 mars 2026

March 15, 2026

An innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections.

Hamlet BioPharma AB
Klinikgatan 32
SE-222 42 Lund
info@hamletbiopharma.com
Org. no. 556568-8958

Subscribe to receive
Pressreleases and Newsletters

Hamlet BioPharma.

Press releases

New discoveries in infection biology, highlighting the rich potential of non-antibiotic treatments of infections

New scientific advances for Alpha1H highlight the unique discovery pipeline and drug development potential for the treatment of bladder cancer

New granted patents added to Hamlet BioPharma’s extensive patent portfolio in cancer and infection

Strong Alpha1H treatment effects confirmed in patients with bladder cancer, in final analysis. Clinical study report is being completed for submission to the FDA.

Hamlet BioPharma bjuder in till investerarmöte den 12 mars

Kommuniké från extra bolagsstämma i Hamlet BioPharma AB (publ) den 11 mars 2025

Hamlet BioPharma bjuder in till investerarmöte den 21 februari

Kallelse till extra bolagsstämma i Hamlet BioPharma AB (publ)

The board of Hamlet BioPharma proposes licensing agreement with Linnane Pharma, which creates conditions for an effective commercialization of Bamlet and positive value ​​for both companies

Elisabeth Parker appointed as Business development expert in Hamlet BioPharma and joins the team on March 3rd

Pressrelease – Lund, March 30th, 2026 – Hamlet BioPharma presented at the Financial Stockholm event on March 26, 2026

Pressrelease – Lund, 24 Mars, 2026 – Hamlet BioPharma tillförs cirka 8.5 miljoner kronor genom teckning av teckningsoptioner serie TO5B, s.k. korta optioner

Pressrelease – Lund, March 17th, 2026 – Hamlet BioPharmas digital monthly investor meeting on the 18th of March

Pressrelease – Lund, 15 mars 2026 – Styrelsen beslutar om justering av villkoren för teckningsoptioner av serie TO5B och inför ny kompletterande teckningsperiod 16-23 mars 2026

The board of Hamlet BioPharma proposes licensing agreement with Linnane Pharma, which creates conditions for an effective commercialization of Bamlet and positive value for both companies